Original Article
A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis
Análisis de las consecuencias en materia de costos del uso preferencial del secukinumab en comparación con el adalimumab para el tratamiento de la artritis psoriásica
Leído
3614
Vecesse ha leído el artículo
1308
Total PDF
2306
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 3 | 15 | 18 |
| 2025 5 | 132 | 63 | 195 |
| 2025 4 | 104 | 42 | 146 |
| 2025 3 | 101 | 34 | 135 |
| 2025 2 | 87 | 27 | 114 |
| 2025 1 | 67 | 46 | 113 |
| 2024 12 | 42 | 32 | 74 |
| 2024 11 | 82 | 69 | 151 |
| 2024 10 | 61 | 37 | 98 |
| 2024 9 | 79 | 31 | 110 |
| 2024 8 | 64 | 44 | 108 |
| 2024 7 | 76 | 38 | 114 |
| 2024 6 | 59 | 42 | 101 |
| 2024 5 | 62 | 40 | 102 |
| 2024 4 | 40 | 21 | 61 |
| 2024 3 | 42 | 30 | 72 |
| 2024 2 | 36 | 32 | 68 |
| 2024 1 | 31 | 32 | 63 |
| 2023 12 | 41 | 32 | 73 |
| 2023 11 | 42 | 39 | 81 |
| 2023 10 | 44 | 29 | 73 |
| 2023 9 | 212 | 37 | 249 |
| 2023 8 | 29 | 12 | 41 |
| 2023 7 | 41 | 33 | 74 |
| 2023 6 | 45 | 31 | 76 |
| 2023 5 | 39 | 22 | 61 |
| 2023 4 | 24 | 10 | 34 |
| 2023 3 | 85 | 28 | 113 |
| 2023 2 | 51 | 31 | 82 |
| 2022 1 | 35 | 31 | 66 |
| 2022 12 | 68 | 36 | 104 |
| 2022 11 | 53 | 36 | 89 |
| 2022 10 | 75 | 27 | 102 |
| 2022 9 | 50 | 31 | 81 |
| 2022 8 | 44 | 39 | 83 |
| 2022 7 | 36 | 33 | 69 |
| 2022 6 | 52 | 34 | 86 |
| 2022 5 | 64 | 40 | 104 |
| 2022 2 | 1 | 2 | 3 |
| 2021 1 | 1 | 0 | 1 |
| 2021 11 | 2 | 2 | 4 |
| 2021 10 | 2 | 0 | 2 |
| 2021 5 | 1 | 2 | 3 |
| 2021 4 | 0 | 6 | 6 |
| 2021 3 | 0 | 2 | 2 |
| 2020 1 | 0 | 2 | 2 |
| 2020 11 | 0 | 3 | 3 |
| 2020 9 | 1 | 3 | 4 |
Mostrar todo
